AT7519 is a potent inhibitor of cyclin-dependent kinases (CDKs), particularly CDK1, CDK2, CDK4, and CDK9. It is primarily investigated for its anticancer properties due to its ability to disrupt cell cycle progression and inhibit transcription in tumor cells. By targeting CDKs, AT7519 induces apoptosis and suppresses proliferation in various cancer cell lines, including leukemia, multiple myeloma, and solid tumors. It has shown promising activity in preclinical models as a single agent and in combination with other chemotherapeutics, enhancing the efficacy of drugs like cytarabine in hematological malignancies. Its ability to downregulate short-lived oncoproteins through CDK9 inhibition makes it especially useful in cancers dependent on rapid protein turnover for survival. AT7519 has advanced into clinical trials for cancer therapy, focusing on its role in patients with relapsed or refractory malignancies. The compound is also used as a research tool to study CDK signaling pathways and their role in cell cycle regulation and transcriptional control.